• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

作者信息

Santoro Armando, Pilar Garrido, Tan Daniel S W, Zugazagoitia Jon, Shepherd Frances A, Bearz Alessandra, Barlesi Fabrice, Kim Tae Min, Overbeck Tobias R, Felip Enriqueta, Cai Can, Eddy Simantini, McCulloch Tracey, Schaefer Eric S

机构信息

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy.

出版信息

BMC Cancer. 2024 Nov 21;24(1):1436. doi: 10.1186/s12885-024-13210-9.

DOI:10.1186/s12885-024-13210-9
PMID:39574037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11580551/
Abstract
摘要

相似文献

1
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.更正：在PD-L1未选择的转移性非小细胞肺癌患者中，斯帕妥珠单抗联合含铂双药化疗（联合或不联合卡那单抗）。
BMC Cancer. 2024 Nov 21;24(1):1436. doi: 10.1186/s12885-024-13210-9.
2
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.斯帕利珠单抗联合含铂双药化疗加或不加卡那奴单抗治疗 PD-L1 未选择的转移性非小细胞肺癌患者。
BMC Cancer. 2024 Oct 24;24(1):1307. doi: 10.1186/s12885-024-12841-2.
3
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.信迪利单抗与其他 PD-L1 抑制剂用于非鳞状非小细胞肺癌一线治疗的间接比较。
Future Oncol. 2022 May;18(15):1896-1905. doi: 10.2217/fon-2021-1336. Epub 2022 Mar 21.
4
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.沙博利单抗联合斯帕利珠单抗治疗既往接受抗 PD-1/PD-L1 治疗的非小细胞肺癌或黑色素瘤患者：一项 2 期多中心研究。
BMJ Open. 2024 Aug 29;14(8):e079132. doi: 10.1136/bmjopen-2023-079132.
5
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.帕博利珠单抗联合化疗与单纯化疗治疗PD-L1＜50%的转移性非鳞状非小细胞肺癌的真实世界数据（RWD）对疗效和进展后结局的分析比较
Front Oncol. 2022 Aug 10;12:980765. doi: 10.3389/fonc.2022.980765. eCollection 2022.
6
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.avelumab 对比含铂双药化疗作为 PD-L1 高表达转移性 NSCLC 患者一线治疗：来自 III 期 JAVELIN Lung 100 试验的主要分析。
J Thorac Oncol. 2024 Feb;19(2):297-313. doi: 10.1016/j.jtho.2023.09.1445. Epub 2023 Sep 24.
7
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.卡那单抗联合一线帕博利珠单抗加化疗对比安慰剂治疗晚期非小细胞肺癌：CANOPY-1试验结果
J Clin Oncol. 2024 Jan 10;42(2):192-204. doi: 10.1200/JCO.23.00980. Epub 2023 Dec 1.
8
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.Spartalizumab（PDR001），一种抗 PD-1 抗体，与化疗相比，在复发性/转移性鼻咽癌患者中的 II 期、随机研究。
Clin Cancer Res. 2021 Dec 1;27(23):6413-6423. doi: 10.1158/1078-0432.CCR-21-0822. Epub 2021 Aug 25.
9
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.FDA 批准概要：帕博利珠单抗、阿替利珠单抗和西米普利单抗-rwlc 作为 PD-L1 高表达晚期/转移性 NSCLC 一线治疗的单药治疗。
Clin Cancer Res. 2022 Jun 1;28(11):2221-2228. doi: 10.1158/1078-0432.CCR-21-3844.
10
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.使用真实世界数据评估PD-(L)1抑制剂单药或联合铂类双药化疗在一线（1L）PD-L1高表达非鳞状非小细胞肺癌（Nsq-NSCLC）中的疗效。
Ann Oncol. 2022 May;33(5):511-521. doi: 10.1016/j.annonc.2022.02.008. Epub 2022 Feb 23.

本文引用的文献

1
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.斯帕利珠单抗联合含铂双药化疗加或不加卡那奴单抗治疗 PD-L1 未选择的转移性非小细胞肺癌患者。
BMC Cancer. 2024 Oct 24;24(1):1307. doi: 10.1186/s12885-024-12841-2.